Updates on Tumor Mutational Burden and the Immunotherapy Biomarker Landscape
Laura Tafe, M.D.
Jonathan Nowak, M.D.,Ph.D.
This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA.
This webinar will act as an overview and update regarding the use of Tumor Mutational Burden (TMB) as a diagnostic and prognostic tool. Advances in massively parallel sequencing technologies has facilitated the large scale examination of the mutational profile of tumors. Best practices with regard to elaboration of these techniques is evolving as is the correlation of results with clinical outcomes. This presentation will provide additional information regarding the newest innovations as well as implications for TMB testing, interpretation, and reporting. Some clinical applications and challenges will be discussed.Learning Objectives:
- Elaborate on the advantages and limitations of TMB molecular diagnostic results.
- Describe the current use of TMB to guide diagnosis and treatment.
- Harness available information to improve implementation of molecularly targeted cancer diagnostics and therapies in the clinical setting.
Recording Date: June 6, 2019
Duration: 1 hr
Level of Instruction: Basic
CME/CMLE credit: 1.00 hour
Last Day to Purchase CE Credit: December 31, 2021
How to claim credit:
To earn CME/CMLE credit, all learners must watch the webinar and then complete the online survey.
AMA PRA Category 1 Credit(s)™
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.
The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.
For more information on this series, please go here.
This program has been supported through an educational grant from Bristol-Myers Squibb.
AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC. IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.
Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.
Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.